HR 2562
115th Congress
House
Health
Administrative remedies
Congressional oversight
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Government information and archives
Prescription drugs
Making Pharmaceutical Markets More Competitive Act
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 26, 2017
Referred to the Subcommittee on Health.
May 19, 2017
Referred to the House Committee on Energy and Commerce.
May 19, 2017
Introduced in House
Plain-English summary
Making Pharmaceutical Markets More Competitive Act
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs.
The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale.
The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2